NVCT

Nuvectis Pharma, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website nuvectis.com
Employees(FY) 11
ISIN US67080T1088

Performance

+11.3%

+1.36%

-15.26%

-19.69%

-37.41%

YTD

-37.78%

Profile

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Advanced Technical Analysis

Technical Analysis of NVCT 2024-12-27

The stock's Moving Average Score of 50 indicates a neutral trend, while the Oscillators Score of 60 suggests a bullish momentum. Overall, the combined Technical Score of 55 reflects a neutral sentiment, indicating that while there are some positive signals, the stock is not yet in a strong bullish phase.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NVCT

Stock Rank

Recent News & Updates

2024-12-09 19:00
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium(Yahoo Finance)
2024-12-09 19:00
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators and Investors Symposium(Globenewswire)
2024-11-24 20:55
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?(Yahoo Finance)
2024-11-14 18:45
Nuvectis Pharma reports data from Phase 1b study of NXP800(Yahoo Finance)
2024-11-14 01:23
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug(Yahoo Finance)
2024-11-13 18:00
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer(Globenewswire)
2024-11-12 19:50
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why(Yahoo Finance)
2024-11-06 20:55
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know(Yahoo Finance)
2024-11-04 18:00
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-10-27 20:21
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update(Businesswire)
2024-10-22 20:00
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics(Globenewswire)
2024-10-06 20:00
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference(Globenewswire)
2024-09-15 19:15
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch(Businesswire)
2024-09-04 20:00
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-29 18:52
Nuvectis NXP800 gains FDA ODD for cancer treatment(Yahoo Finance)
2024-08-28 20:00
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers(Globenewswire)
2024-08-05 20:28
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-05-27 18:10
7 Penny Biotech Stocks to Triple Your Investment(Investorplace)
2024-05-23 21:55
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?(Zacks)
2024-05-15 20:30
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference(Globenewswire)
2024-05-07 09:06
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes(Yahoo Finance)
2024-05-07 01:53
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024(Investorplace)
2024-05-06 20:00
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-04-07 20:30
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines(Globenewswire)
2024-04-02 04:30
5 Healthcare Stocks to Buy for 2024(Yahoo Finance)
2024-03-18 20:00
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting(Globenewswire)
2024-03-14 20:00
Nuvectis Pharma to Present at the 36th Annual Roth Conference(Yahoo Finance)
2024-03-13 21:00
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer(Globenewswire)
2024-03-05 10:52
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023(Investorplace)
2024-03-04 19:31
Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.